Abstract: Prophylaxis and treatment of patients susceptible to infection by coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is achieved using compositions including one or more inhibitors including sulfated glycans and/or highly negative charged compounds. The inhibitors bind to wild-type and variant spike glycoproteins (S-proteins or SGPs) of SARS-CoV-2, inhibiting fusion, entry, and infection of a host cell. The inhibitors can include pentosan polysulfate (PPS), mucopolysaccharide polysulfate (MPS), sulfated lactobionic acid, sulodexide, a defibrotide, 4-t-butylcalix[X] arene-p-sulfonic acid, or combinations thereof. The presence of additional sulfo groups in PPS and MPS contribute to the improved inhibitory activity of compositions with those sulfated glycans against COVID-19 compared with compositions containing heparin alone.

Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Abstract: Provided are methods and uses of polyoxyethylene/polyoxypropylene copolymers (poloxamers) for treating bleeding and hemorrhage in animals, including human or veterinary subjects, and thus, treating hemostatic dysfunction, resulting from, for example, drug, disease-, trauma- or surgical-induced bleeding. Polyoxyethylene/polyoxypropylene copolymers improve hemostasis and aid in the control of bleeding. Methods for treating strokes using the polyoxyethylene/polyoxypropylene copolymers also are provided. Devices, products and compositions for treating or preventing hemostatic dysfunction are provided.

Abstract: The present invention relates to the use of glycosaminoglycan fractions having an average molecular weight of 2400 (±200) D for the preparation of pharmaceutical compositions suitable for the treatment of emotional dysfunctions, especially depressive disorders, anxiety disorders, anxiety neurosis, agitation, confusion.

Abstract: The present invention relates to the use of glycosaminoglycan fractions having an average molecular weight of 2400 (?200) D for the preparation of pharmaceutical compositions suitable for the treatment of emotional dysfunctions, especially depressive disorders, anxiety disorders, anxiety neurosis, agitation, confusion.

Abstract: The present invention relates to the use of glycosaminoglycans having an average/molecular weight of 2,400 D for the preparation of pharmaceutical compositions suitable for the treatment of senile dementia, in particular for the treatment of Alzheimer's disease or SDAT (Senile Dementia Alzheimer's Type) and of the cerebral neurological lesions from ictus and from traumas.